204913-01-9 Usage
Description
1-[(3S,1R)-3-N-BOC-aminocyclopentyl]-1-ethanone is a cyclopentylamine derivative with the chemical formula C13H23NO3. It features a specific arrangement of atoms, with the "BOC" group indicating the presence of a tert-butyloxycarbonyl protective group for amines. 1-[(3S,1R)-3-N-BOC-aminocyclopentyl]-1-ethanone is significant in the development of new drugs and bioactive compounds, serving as a valuable building block in organic chemistry research.
Uses
Used in Pharmaceutical Synthesis:
1-[(3S,1R)-3-N-BOC-aminocyclopentyl]-1-ethanone is used as an intermediate in the synthesis of pharmaceuticals for its ability to protect amines from unwanted reactions during the drug development process.
Used in Organic Chemistry Research:
In the field of organic chemistry, 1-[(3S,1R)-3-N-BOC-aminocyclopentyl]-1-ethanone is utilized as a building block for the creation of various organic compounds, contributing to the advancement of chemical knowledge and the development of novel substances.
Check Digit Verification of cas no
The CAS Registry Mumber 204913-01-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,4,9,1 and 3 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 204913-01:
(8*2)+(7*0)+(6*4)+(5*9)+(4*1)+(3*3)+(2*0)+(1*1)=99
99 % 10 = 9
So 204913-01-9 is a valid CAS Registry Number.
204913-01-9Relevant articles and documents
1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE
-
Paragraph 0336; 0479; 0480, (2021/09/24)
The purpose of the present invention is to provide a compound having PIM inhibitory activity. Examples of the present invention include 1,3,4-oxadiazolone compounds represented by the following formula [1], and pharmaceutically acceptable salts, and solvates thereof. The compounds of the present invention have PIM inhibitory activity. In addition, since the compounds of the present invention have PIM inhibitory activity, the compounds of the present invention are useful as therapeutic agents for systemic lupus erythematosus, lupus nephritis, etc.
